The information provided is for convenience only. It is not investment advice or a recommendation, it does not constitute a solicitation to buy or sell securities, and it may not be relied upon in considering an investment in a Cardone fund. Past performance is no guarantee of future results. Any historical returns expected returns or probability projections may not reflect actual future performance. All securities involve risk and may result in partial or total loss. Investment in Cardone funds is available only to independently verified “accredited investors” through an offering made in accordance with Rule 506(c) under Regulation D of the Securities Act of 1933. Before investing in any Cardone fund, prospective investors should consider carefully the investment objective(s), risks, arches, and expenses. While the data we use from third parties is believed to be reliable, we cannot ensure the accuracy or completeness of the data provided. Cardone Capital does not provide legal or tax advice. Prospective investors should consult with a tax or legal adviser before making any investment decision.

The Magic Cure – David C. Karli

In this Show

David C. Karli’s regenerative medicine is improving every day and it is a step closer to being the magic cure. He is now at a point where he can study biomedicine in a sophisticated enough way to improve a step further.

Get in contact with David C. Karli through his website, LinkedIn, and learn more about Greyledge Technologies here:

davidkarli.com

https://www.linkedin.com/in/davidkarli/

https://www.greyledgebiotech.com/

 

I started like everyone else, using tabletop devices that were very simple and would process a sample. And I didn’t know what was in it, and I just didn’t feel comfortable with that. We had to be able to do better. We had to be able to do it better.

We started digging and looking as to how could I at least know what’s in it? Before thoughts of a company or before thoughts of field, before thoughts of anything, and I had this little tool that seemed cool and it seemed to make a lot of sense, and we were seeing some improvement in patients. I just wanted to know what’s in it. How do we do anything with it if we don’t know what’s in it? It started as that.

We looked at technology to measure what was in it, there was no guidance. We had to just try different things. We started out in the early days looking through a microscope, counting with a manual counter, which at the end of the day, you can imagine the headache that you had.

We started with that, and it just evolved, and evolved. We’re several generations into technology now to analyze what’s in there, and we can do it in 30 seconds, and get an incredibly sophisticated analysis of every cell, every cell population, the number of cells, the concentrations; an incredible breakdown.

The first step was let’s just know what’s in it, if for no other reason, then to make sure our patient was safe.

What Karli and his team are fascinated to find out in the future about is if the concept of off-the-shelf stem cell product will turn into a reality and if it will be any better than what they can do today.

He is sure that with his extremely capable team on the clinical and research end this dream can become a reality.

(Visited 25 times, 1 visits today)